Korro Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Korro Bio Inc KRRO.OQ reported a quarterly adjusted loss of $2.74​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-2.43. The mean expectation of ten analysts for the quarter was for a loss of $2.56 per share. Wall Street expected results to range from $-3.41 to $-2.07 per share.

• Revenue was $1.46 million​; analysts expected $508.63 thousand.

• Korro Bio Inc's reported EPS for the quarter was a loss of $2.74​.

• The company reported a quarterly loss of $25.77 million.

• Korro Bio Inc shares had risen by 20.5% this quarter and lost 60.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Korro Bio Inc is $90.00, about 83.3% above its last closing price of $15.05

This summary was machine generated from LSEG data August 12 at 11:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)